Adagene

Yahoo Finance • 20 days ago

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that ADG126 w... Full story

Yahoo Finance • 22 days ago

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos a... Full story

Yahoo Finance • 30 days ago

Adagene to Participate in Two Investor Conferences in September

SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s... Full story

Yahoo Finance • last month

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements. Company expects to beg... Full story

Yahoo Finance • 2 months ago

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen - Company expects to begin enrolling patients in Phase 2 in 2H 2025 SAN DIEGO and SUZ... Full story

Yahoo Finance • 3 months ago

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company trans... Full story

Yahoo Finance • 3 months ago

Adagene gains as Sanofi collaboration expands

[Collaboration concept in word tag cloud] rafal_olechowski * Adagene (NASDAQ:ADAG [https://seekingalpha.com/symbol/ADAG]) ADRs added ~16% in the premarket on Tuesday after Sanofi (NASDAQ:SNY [https://seekingalpha.com/symbol/SNY]) expand... Full story

Yahoo Finance • 3 months ago

Adagene announces up to $25 million strategic investment from Sanofi

- Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - Company expects proceeds to extend cash runway into 2027 SAN DIEGO and SUZHOU, China, July 01, 2025 (GLOBE NEWSWIR... Full story

Yahoo Finance • 4 months ago

Adagene to Present at Jefferies Global Healthcare Conference 2025

SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy... Full story

Yahoo Finance • 4 months ago

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable... Full story

Yahoo Finance • 5 months ago

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASC... Full story

Yahoo Finance • 6 months ago

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEbody technology utilized to create masked T cell engagers for potentially superior... Full story

Yahoo Finance • 6 months ago

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its presentation at the 11th... Full story

Yahoo Finance • 8 months ago

Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

SAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will share updated clinica... Full story

Yahoo Finance • 2 years ago

Adagene Inc.'s (NASDAQ:ADAG) market cap surged US$34m last week, retail investors who have a lot riding on the company were rewarded

Key Insights The considerable ownership by retail investors in Adagene indicates that they collectively have a greater say in management and business strategy 52% of the business is held by the top 6 shareholders Insiders own 19% of Adage... Full story

Yahoo Finance • 2 years ago

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab – - Integrated pharmacokinetic and clinical data analyse... Full story

Yahoo Finance • 2 years ago

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

- Data reinforces mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort – SAN DIEGO and SUZHOU, China, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Adagene... Full story

Yahoo Finance • 2 years ago

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

- Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical responses, pave way for dose expansion in specific tumors - - Tumor shrinkage and prolonged stable... Full story

Yahoo Finance • 3 years ago

Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

- Clinical posters detail results of dose escalation portion of phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, demonstrating benefits of SAFEbody precision masking technology - - Additional poster reports preclinical... Full story

Yahoo Finance • 3 years ago

Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board

- Brings deep insight in tumor-specific Treg depletion for anti-CTLA-4 therapies delivered intratumorally to overcome dose dependent toxicities - - Expertise contributes to Adagene’s novel anti-CTLA-4 therapies delivered systemically at h... Full story